Detalles de la búsqueda
1.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Nature
; 629(8014): 1142-1148, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38588696
2.
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
BMC Med
; 22(1): 9, 2024 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38191387
3.
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Int J Gynecol Cancer
; 33(12): 1966-1969, 2023 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37935524
4.
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Int J Cancer
; 151(8): 1394-1404, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35583992
5.
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Br J Cancer
; 126(10): 1401-1409, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35124703
6.
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
Int J Cancer
; 148(12): 3041-3050, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539540
7.
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Nature
; 521(7553): 541-544, 2015 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25799992
8.
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Breast Cancer Res
; 19(1): 99, 2017 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28851423
9.
Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
Int J Cancer
; 151(11): 2057-2058, 2022 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35857410
10.
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
Int J Cancer
; 139(4): 882-9, 2016 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26946057
11.
Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
Genes Chromosomes Cancer
; 54(12): 734-44, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26355282
12.
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
JAMA Netw Open
; 7(4): e245552, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38592722
13.
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
Breast Cancer Res Treat
; 139(2): 317-27, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23670131
14.
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
Cancers (Basel)
; 14(23)2022 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497449
15.
Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.
Clin Cancer Res
; 27(23): 6559-6569, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593530
16.
Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.
Oncoimmunology
; 9(1): 1724049, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32117586
17.
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Clin Cancer Res
; 25(3): 1087-1097, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30413523
18.
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
Clin Cancer Res
; 25(14): 4351-4362, 2019 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31036541
19.
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Nat Med
; 25(6): 920-928, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31086347
20.
Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Nat Med
; 25(7): 1175, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31209337